Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dexamethasone + KTX-1001 + Pomalidomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dexamethasone | Adexone | Desametasone | ||
| KTX-1001 | KTX 1001|KTX1001 | KTX-1001 is a selective inhibitor of NSD2 (MMSET), which potentially inhibits tumor cell growth and induces antitumor activity (Blood (2024) 144 (Supplement 1): 3370, NCI Drug Dictionary). | ||
| Pomalidomide | Pomalyst | CC-4047 | Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05651932 | Phase I | KTX-1001 CC-92480 + Dexamethasone + KTX-1001 Dexamethasone + KTX-1001 Dexamethasone + KTX-1001 + Pomalidomide Carfilzomib + Dexamethasone + KTX-1001 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | CAN | 0 |